Health Insurance Stocks Plummet Following UnitedHealthcare CEO’s Murder in New York
New York, NY – October 11, 2025, Shares of major U.S. health insurance companies, including UnitedHealth Group (UNH), have taken a significant hit in the wake of the shocking murder of UnitedHealthcare CEO Brian Thompson on December 4, 2024, outside a Manhattan hotel. The targeted killing of Thompson, who led the nation’s largest private health insurer, has ignited a firestorm of public scrutiny and renewed criticism of the industry’s practices, contributing to a sharp decline in stock prices across the sector.
According to real-time financial data, UnitedHealth Group’s stock (UNH) closed at $354.50 on October 10, 2025, reflecting a 3.6% drop from the previous day’s close of $367.69, as shown in the finance card above. Over the past month, UNH has seen volatility, dipping from $370.70 on October 8 to a low of $334.9983 on September 18, with a year-to-date decline of approximately 35% from its January 2025 value of $542.49. The broader sector has also been rattled, with Cigna Group and CVS Health each falling around 4% on a single day last week, and Elevance Health dropping 2% over five days following Thompson’s death.
Thompson, 50, was fatally shot in Midtown Manhattan in what New York police described as a “targeted attack” by 26-year-old Luigi Mangione, who was arrested days later in Altoona, Pennsylvania. Mangione’s manifesto, found by police, revealed deep-seated resentment toward corporate America, particularly the health insurance industry, with shell casings at the scene inscribed with words like “deny,” “defend,” and “depose”—a nod to a 2010 book critical of insurers’ claim denial practices. The incident, occurring just before UnitedHealth’s annual investor meeting, unleashed a torrent of social media outrage, with posts highlighting frustrations over denied claims, high costs, and the complexity of navigating coverage.
The fallout has been swift and severe. UnitedHealth’s market value has reportedly shed $63 billion since the murder, with shares dropping roughly $100 from $610 on December 4, 2024, to around $510 by mid-January 2025, though the finance card above indicates a further decline to $354.50 by October 10. Rival insurers like Cigna, CVS Health, and Centene also saw declines ranging from 1% to 3% in the days immediately following the shooting, driven by what analysts call “renewed negative rhetoric” about the industry’s business models. Jared Holz, a health-care equity strategist at Mizuho, noted that investors are wary of owning insurance stocks amid heightened scrutiny, questioning whether the public backlash could lead to long-term regulatory or legislative challenges.
Adding to UnitedHealth’s woes, a class-action lawsuit filed in May 2025 in the Southern District of New York accuses the company of misleading shareholders by failing to adjust its 2025 earnings guidance after Thompson’s killing. The suit claims UnitedHealth stuck to an overly optimistic forecast of $29.50–$30.00 per share in adjusted net earnings, despite internal shifts away from aggressive claim denial strategies due to public and regulatory pressure. On April 17, 2025, UnitedHealth slashed its forecast to $26–$26.50 per share, citing higher Medicare costs, triggering a single-day stock plunge of 22.4% to $454.11 and wiping out $119 billion in market value.
Despite the stock rout, UnitedHealth reported better-than-expected Q4 2024 earnings of $6.81 per share, up 10.6% year-over-year, with revenues of $100.8 billion. However, analysts like Morningstar’s Julie Utterback suggest the industry may need to rethink coverage decisions to mitigate risks to profitability, as public anger—fueled by viral discussions of denied claims—shows no signs of abating. Posts on X reflect mixed sentiment, with some users like @thexcapitalist noting UNH’s undervaluation potential despite volatility, while others, like @adammocklerr, criticize the industry’s broader impact on healthcare affordability.
The murder has also prompted security measures, with UnitedHealth and CVS removing executive photos from their websites, and a Senate report highlighting the use of AI to deny care adding fuel to the fire. While Holz predicts the stock reaction may be “fairly short-lived,” the industry faces an uphill battle to restore public trust. For now, Thompson’s killing has exposed deep-seated frustrations with U.S. healthcare, leaving investors and insurers grappling with the consequences.